In individuals with metabolic syndrome or obesity, circulating FGF19 levels are reduced, whereas CYP7A1 expression and total bile acid pool size are increased in type 2 diabetes, suggesting disruption of the negative FXR/FGF19 feedback loop [147]. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.